Search Beyond News…

CordenPharma expands aseptic fill‑finish capacity to 500 million sterile injectable units per year with an €80 million multi‑year investment

Executive summary: CordenPharma announced a multi‑year €80 million investment to build a new facility and install additional aseptic fill‑finish lines in Basel, aiming to reach 500 million sterile injectable units per year. The expansion increases CordenPharma’s capacity to serve growing demand for sterile injectables, strengthening its CDMO offering in Europe and potentially attracting new biotech and pharma partners.

Who is involved: CordenPharma (CDMO), its Basel site, and the investors providing the €80 million multi‑year funding.

Likely next: Construction and installation of the new lines will proceed over the coming months, with capacity expected to become operational by late 2027; the company may seek additional supply contracts to utilize the added capacity.

CordenPharma’s announcement details a multi‑year €80 million investment to construct a new facility and add aseptic fill‑finish lines in Basel, Switzerland, targeting an annual output of 500 million sterile injectable units. The move aims to meet rising demand for sterile injectables from biotech and pharmaceutical clients, reinforcing CordenPharma’s position as a contract development and manufacturing organization in Europe. While the investment signals confidence in the sterile injectable market, the actual ramp‑up will depend on construction timelines and customer uptake.

What's next — scenarios

Base case: on‑schedule rollout (50%)

Steady revenue increase for CordenPharma as the new fill‑finish lines enter service as planned.

Upside: early uptake (30%)

Higher‑than‑expected revenue and potential for additional capacity expansion due to strong early customer demand.

Downside: delays or weak demand (20%)

Underutilization of the new capacity, putting pressure on the return on the €80 million investment.

What to watch

Timeline

Analysis — what this means

Sectors affected

Historical parallels

Key entities

Sources

Related cases

Browse the full archive →